Aggrecan Antibody, N-terminal neoepitope ARG, 100 ug
Aggrecan monoclonal antibody to N-terminal neoepitope ARG (mouse, clone BC-3). Aggrecan degradation products containing this neoepitope are rapidly released from the tissue in model explant culture systems and are also present...
Aggrecan monoclonal antibody to N-terminal neoepitope ARG (mouse, clone BC-3). Aggrecan degradation products containing this neoepitope are rapidly released from the tissue in model explant culture systems and are also present in the synovial fluids of patients with degenerative joint disease.
During differentiation of neural precursor cells, neurospheres downregulate Chondroitin sulfate proteoglycans (CSPGs). Proliferating neural precursors synthesize lecticans, including aggrecan, which are downregulated with differentiation; suggesting a link between CSPGs and CNS precursor biology.
Brebion, F., Gosmini, R., Deprez, P., Varin, M., Peixoto, C., Alvey, L., ... & Amantini, D. (2021). Discovery of GLPG1972/S201086, a Potent, Selective, and Orally Bioavailable ADAMTS-5 Inhibitor for the Treatment of Osteoarthritis. Journal of Medicinal Chemistry, 64(6), 2937-2952.
Product Insert (PDF) - Informational use only. Please refer to insert included with product.
- Immunogen: ARGSV synthetic peptide conjugate.
- Clone: BC-3
- Host: Mouse
- Myeloma: x63-Ag8.653
- Isotype: IgG1
- Light Chain type: kappa
- Specificity: Recognizes the aggrecanase (ADAMTS-1, -4 & -5)-generated N-terminal neoepitope ARG after cleavage between amino acids EGE and ARG within the interglobular domain of aggrecanase-catabolised aggrecan (Human aggrecan sequence enumeration). This antibody will not recognize the sequence ARG if it is in the non-cleaved intact aggrecan protein core; i.e. it will only recognize the aggrecanase generated neoepitope ARG.
- Cross-reactivity: human, rat, cat, cow, dog, guinea pig, horse, pig, rabbit and sheep.
- Purity: Affinity purified on protein G
- Form: Liquid, 1 mL/vial
- Concentration: 0.1 mg/mL